Two Sigma Securities’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Two Sigma Securities’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-3,300	Closed	-$435K	–	2248
2025 Q1	$435K	Sell	3,300 -1,339	-29%	-$167K	0.07%	406
2024 Q4	$387K	Buy	+4,639	New	+$381K	0.05%	504
2022 Q1	–	Sell	-8,779	Closed	-$459K	–	2603
2021 Q4	$459K	Buy	+8,779	New	+$369K	0.02%	574
2017 Q4	–	Sell	-21,219	Closed	-$335K	–	2066
2017 Q3	$335K	Buy	+21,219	New	+$311K	0.03%	366

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Two Sigma Securities's ITCI Position: Q2 2025 in Review

Two Sigma Securities sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 3,300 shares — an estimated $435K sold.

Two Sigma Securities first reported a position in ITCI in Q3 2017 and held it in 4 quarters. The position peaked at $459K in Q4 2021. 3 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Two Sigma Securities reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Two Sigma Securities sold 3,300 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $435K.
Two Sigma Securities first reported a position in Intra-Cellular Therapies Inc. in Q3 2017 and held it in 4 quarters.
Two Sigma Securities's Intra-Cellular Therapies Inc. position peaked at $459K in Q4 2021.
3 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Two Sigma Securities's 13F filing for Q2 2025, filed 14 Aug 2025.